In intrahepatic cholangiocarcinoma (iHCC), losartan reduced stromal density by inhibiting YAP1/LAT1 dephosphorylation and MFAP5-mediated Notch1 signalling from AT1R+ CAFs [55] (Fig. 1). Here, YAP1 is linked to intrahepatic cholangiocarcinoma.